Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis
1 finding from 1 review
Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease · people with systemic sclerosis
1 finding from 1 review
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with systemic sclerosis
Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Restoration failure · Children with carious primary teeth after vital or non-vital pulp therapy
In one RCT, selective caries removal had a 3.44 higher probability of failure than complete caries removal.
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).
1 finding from 1 review
Dropout · adults living with HIV and depression
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in study dropouts at 6‐12 weeks compared with atypical agent (low certainty).
1 finding from 1 review
Dropout · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
Efficacy as a continuous outcome · patients with cancer and depression
1 finding from 1 review
Efficacy as a dichotomous outcome · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Overall mortality · people with systemic sclerosis
1 finding from 1 review
Event‐free survival · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional ability · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found